Shattuck Labs Q1 net loss $13.7M, cash $60.9M; SL-325 IND filing expected Q3 2025

Shattuck Labs, Inc.

2025-Q1 EPS reported -$0.27

Net loss of $13.7M ($0.27 per share) for Q1 2025 compared to $18.5M ($0.37 per share) in Q1 2024.
Cash and equivalents of $60.9M as of Mar 31, 2025, expected to fund operations into 2027.
SL-325 IND filing expected in Q3 2025; Phase 1 SAD portion first patient in Q3 2025, enrollment complete Q2 2026.
R&D expenses decreased to $9.9M from $16.3M YoY; G&A expenses decreased to $4.5M from $4.9M.
Wind-down activities for discontinued oncology programs substantially completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.